Motivational Enhancement for Spanish Speaking Individuals - 1

This study has been completed.

First Received on February 19, 2004. Last Updated on April 13, 2010 History of Changes

Sponsor:	Yale University
Collaborator:	University of Miami
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00078169

Purpose

The purpose of this study is to compare a three-session Spanish version of Motivational Enhancement Therapy (MET) to standard treatment to see how well MET engages and retains Spanish-speaking clients in outpatient substance abuse treatment.

Condition	Intervention	Phase
Substance-Related Disorders	Behavioral: Behavior Therapy	Phase III

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Motivational Enhancement for Spanish Speaking Individuals

Resource links provided by NLM:

MedlinePlus related topics: Drug Abuse

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Treatment retention, drug and alcohol abstinence

Estimated Enrollment:	463
Study Start Date:	November 2003
Study Completion Date:	October 2005
Primary Completion Date:	October 2005 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

All subjects included unless medical/psychiatrically unstable

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00078169

Locations

United States, Colorado
Island Grove RTC
Greeley, Colorado, United States, 80631
United States, Florida
Miami Behavioral Health
Miami, Florida, United States, 33161
United States, New Mexico
Counseling & Psychotherapy Institute
Albuquerque, New Mexico, United States, 87194
The Life Link
Santa Fe, New Mexico, United States, 87505
United States, New York
Narco Freedom (Bridge Plaza)
Long Island City, New York, United States, 11101
United States, Oregon
Changepoint, Inc.
Portland, Oregon, United States, 97402
Changepoint - Cedar Hills Blvd
Portland, Oregon, United States, 97292

Sponsors and Collaborators

Yale University

University of Miami

Investigators

Principal Investigator:

Kathleen Carroll, Ph.D.

Yale University

More Information

No publications provided

Responsible Party:	Kathleen Carroll, Ph.D., Yale University School of Medicine
ClinicalTrials.gov Identifier:	NCT00078169 History of Changes
Other Study ID Numbers:	NIDA-CTN-0021-1
Study First Received:	February 19, 2004
Last Updated:	April 13, 2010
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Substance-Related Disorders
Mental Disorders

ClinicalTrials.gov processed this record on February 12, 2012